Research programme: antibacterials - FerrerAlternative Names: GF-013062-00; GF-016469-00; GF-016509-00
Latest Information Update: 09 Jan 2009
At a glance
- Originator Ferrer
- Class Oxazolidinones
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Gram-positive infections
Most Recent Events
- 09 Jan 2009 Preclinical development is ongoing in Spain
- 03 Oct 2007 Preclinical development is ongoing